Pricing Log in Create free account
Friday 6 November 2026 Export SEPN’s income statement to Excel — free account

Septerna, Inc.

SEPN Healthcare Biotechnology

Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.

Revenue
+22,375.6%
EPS
+48.2%
Free cash flow
−9.01%

Quarter to June 2026, against a year earlier

49.54 2.19 +4.63%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−32.6×
Dividend yield
—
F-score
5/9
Altman Z
3.41
Beneish M
32.85
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Septerna, Inc. (SEPN) EBITDA

Alert me on EBITDA

Septerna, Inc.'s EBITDA for fiscal 2025 was −$66.7M, compared with −$79.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$41.9M. Septerna, Inc. ranks 300th of 594 Biotechnology companies by EBITDA.

EBITDA, annual

Embed this chart

Annual newest first

Period EBITDA Change
FY2025 −$66.7M —
FY2024 −$79.4M —
FY2023 $2.9M —

Quarterly newest first

Period EBITDA Change
Jun 2026 −$16.4M —
Mar 2026 −$12.9M —
Dec 2025 −$15.6M —
Sep 2025 $3.0M —
7 more quarters

EBITDA against peers

Company EBITDA
AUPH Aurinia Pharmaceuticals Inc compare $163.4M
VCEL Vericel Corporation compare $31.3M
SEPN Septerna, Inc. −$41.9M
PVLA Palvella Therapeutics, Inc. compare −$57.7M
ZYME Zymeworks Inc. compare −$146.1M
IMNM Immunome, Inc. compare −$268.3M
LKFT Lakefront Biotherapeutics - Sponsored ADR compare −$416.8M
VERA Vera Therapeutics, Inc. compare −$417.0M
BHVN Biohaven Ltd. compare −$515.1M

What EBITDA is

EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.

Reported line item

The full definition of EBITDA →

More on SEPN